To take the next leap forward in cancer therapy, we must look back and understand the drivers of treatment resistance, cancer relapse and metastasis.
President & CEO
President & CEO
Despite recent advancements, the current cancer treatment paradigm has failed to achieve durable responses in most cancers due to the development of treatment resistance, relapse and metastasis.
Our research suggests that activation of stress, common across a wide range of cancers and precision therapeutic classes, could result in the activation of responsive stress mitigating pathways and immune suppression in the tumor microenvironment. As a result, cancer cells cope with the stress by altering their phenotype and reprogramming the tumor microenvironment to enable their survival in these stressful conditions, enabling them to achieve resistance and metastasis.
Our clinical-stage therapeutic candidates are designed to modulate these critical pathways and represent a novel approach for addressing treatment resistance, cancer relapse and metastasis.
HiberCell was launched in 2019 with investor support from ARCH Venture Partners and other leading life science investors. With our focus on targeting stress-driven vulnerabilities, we have developed a portfolio of therapeutic candidates with the potential to improve the lives of cancer patients.
In addition to our internal capabilities, we leverage industry leading collaborators to analyze complex proprietary data sets that enable novel phenotypic insights and clinical-genomic observations that we believe will help identify patients who are most likely to respond to our therapeutic candidates. We believe that this approach will allow us to generate clinically actionable insights into adaptive stress pathways.